Highlights
- •Treatment with clopidogrel may induce stroke recurrence in CYP2C19 LoF carriers.
- •High dose of clopidogrel shows secondary outcomes in poor metabolizer CAD patients.
- •Asian CYP2C19*2/*3 carrier population has a significantly higher risk of stroke.
- •Increasing doses of clopidogrel do not reduce risk in polymorphism carrier patients.
- •Caucasian, Hispanic and other ethnic populations show significant risk association.
Abstract
Background
Aim
Methods
Results
Conclusion
Graphical abstract

Keywords
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Internal MedicineReferences
- Interaction of CYP2C19, P2Y12, and GPIIIa Variants Associates with Efficacy of Clopidogrel and Adverse Events on Patients with Ischemic Stroke.Clin Appl Thromb. 2017; 23: 761-768https://doi.org/10.1177/1076029616648408
- Variants in clopidogrel-relevant genes and early neurological deterioration in ischemic stroke patients receiving clopidogrel.BMC Neurol. 2020; 20: 1-8https://doi.org/10.1186/s12883-020-01703-6
- 2020 Heart Disease & Stroke Statistical Update Fact Sheet Global Burden of Disease.Circulation. 2020; 141: 9-11
- High on-clopidogrel platelet reactivity in ischaemic stroke or transient ischaemic attack: Systematic review and meta-analysis.J Stroke Cerebrovasc Dis. 2020; 29https://doi.org/10.1016/j.jstrokecerebrovasdis.2020.104877
- Clopidogrel Resistance Increases Rate of Recurrent Stroke and Other Vascular Events in Chinese Population.J Stroke Cerebrovasc Dis. 2016; 25: 1222-1228https://doi.org/10.1016/j.jstrokecerebrovasdis.2016.02.013
- The phenomenon of clopidogrel high on-treatment platelet reactivity in ischemic stroke subjects: A comprehensive review.Int J Mol Sci. 2020; 21: 1-13https://doi.org/10.3390/ijms21176408
- Genetic polymorphisms and drug interactions leading to clopidogrel resistance: Why the asian population requires special attention.Int J Neurosci. 2013; 123: 143-154https://doi.org/10.3109/00207454.2012.744308
- CYP2C19 Genotype, Clopidogrel Metabolism, Platelet Function, and Cardiovascular Events A Systematic Review and Meta-analysis.JAMA - J Am Med Assoc. 2011; 306: 2704-2714
- Relationship between smoking and responsiveness to clopidogrel in non-cardiogenic ischemic stroke patients.Intern Med. 2014; 53: 2575-2579https://doi.org/10.2169/internalmedicine.53.2918
- Drug Insight: Clopidogrel nonresponsiveness.Nat Clin Pract Cardiovasc Med. 2006; 3: 387-395https://doi.org/10.1038/ncpcardio0602
- Resistance to clopidogrel: A review of the evidence.J Am Coll Cardiol. 2005; 45: 1157-1164https://doi.org/10.1016/j.jacc.2005.01.034
- Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCI: A Meta-Analysis.JAMA - J Am Med Assoc. 2010; 304: 1821-1830https://doi.org/10.1001/jama.2010.1543.Reduced-Function
- Pharmacogenomic impact of CYP2C19 variation on clopidogrel therapy in precision cardiovascular medicine.J Pers Med. 2018; 8: 1-31https://doi.org/10.3390/jpm8010008
- Molecular mechanisms of genetic variation and transcriptional regulation of CYP2C19.Front Genet. 2012; 3: 1-8https://doi.org/10.3389/fgene.2012.00206
- The Personalization of Clopidogrel Antiplatelet Therapy: The Role of Integrative Pharmacogenetics and Pharmacometabolomics.Cardiol Res Pract. 2017; (2017)https://doi.org/10.1155/2017/8062796
- Transcriptional Regulation of CYP2C19 and its Role in Altered Enzyme Activity.Curr Drug Metab. 2012; 13: 1196-1204https://doi.org/10.2174/138920012802850146
- Regulatory polymorphisms in CYP2C19 affecting hepatic expression.Drug Metabol Drug Interact. 2013; 28: 23-30https://doi.org/10.1515/dmdi-2012-0038
- CYP2C19 pharmacogenetics versus standard of care dosing for selecting antiplatelet therapy in patients with coronary artery disease: A meta-analysis of randomized clinical trials.Catheter Cardiovasc Interv. 2019; 93: 1246-1252https://doi.org/10.1002/ccd.27949
- Association of clopidogrel high on-treatment reactivity with clinical outcomes and gene polymorphism in acute ischemic stroke patients: An observational study.Medicine (Baltimore). 2020; 99: e19472https://doi.org/10.1097/MD.0000000000019472
- Effect of high-dose clopidogrel according to CYP2C19∗2 genotype in patients undergoing percutaneous coronary intervention- a systematic review and meta-analysis.Thromb Res. 2015; 135: 449-458https://doi.org/10.1016/j.thromres.2014.12.007
- Genetic polymorphisms and clopidogrel efficacy for acute ischemic stroke or transient ischemic attack.Circulation. 2017; 135: 21-33https://doi.org/10.1161/CIRCULATIONAHA.116.024913
- Carriage of the CYP2C19*2 allele increases one-year risk of myocardial infarction among recipients of drug-eluting stents treated with clopidogrel [abstract 27].J Am Coll Cardiol. 2009; 53: 2903-2908
- CYP2C19 and CES1 polymorphisms and efficacy of clopidogrel and aspirin dual antiplatelet therapy in patients with symptomatic intracranial atherosclerotic disease.J Neurosurg. 2016; 124: 1746-1751https://doi.org/10.3171/2015.6.JNS15795
Bhatt D, Simonsen K, Emison E. CHARISMA genomics substudy: evaluation of the CYP2C19 polymorphism in a prospective, randomized, placebo-controlled trial of chronic clopidogrel use for primary and secondary prevention 2009.
- The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: The CHARISMA genetics study.Eur Heart J. 2012; 33: 2143-2150https://doi.org/10.1093/eurheartj/ehs059
- Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19*2 loss of function polymorphism.J Am Coll Cardiol. 2010; 56: 1630-1636https://doi.org/10.1016/j.jacc.2010.07.004
- Paraoxonase-1 is a major determinant of clopidogrel efficacy.Nat Med. 2011; 17: 110-116https://doi.org/10.1038/nm.2281
- Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention: Relationship with gene polymorphisms and clinical outcome.J Am Coll Cardiol. 2011; 57: 2474-2483https://doi.org/10.1016/j.jacc.2010.12.047
- Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.JACC Cardiovasc Interv. 2018; 11: 181-191https://doi.org/10.1016/j.jcin.2017.07.022
- Influences of an NR1I2 polymorphism on heterogeneous antiplatelet reactivity responses to clopidogrel and clinical outcomes in acute ischemic stroke patients.Acta Pharmacol Sin. 2019; 40: 762-768https://doi.org/10.1038/s41401-018-0178-4
- Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.Lancet. 2009; 373: 309-317https://doi.org/10.1016/S0140-6736(08)61845-0
- Genetic polymorphism of CYP2C19 and inhibitory effects of ticagrelor and clopidogrel towards post-percutaneous coronary intervention (PCI) platelet aggregation in patients with acute coronary syndromes.Med Sci Monit. 2016; 22: 4929-4936https://doi.org/10.12659/MSM.902120
- Association of CYP2C19 gene polymorphisms with long-term recurrent risk of ischemic stroke among ethnic Han Chinese from Fujian.Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2015; 32 ([Association): 871-876https://doi.org/10.3760/cma.j.issn.1003-9406.2015.06.026
- Pharmacogenetic and clinical predictors of response to clopidogrel plus aspirin after acute coronary syndrome in Egyptians.Pharmacogenet Genomics. 2018; 28: 207-213https://doi.org/10.1097/FPC.0000000000000349
- Relation of Cytochrome P450 2C19 Loss-of-Function Polymorphism to Occurrence of Drug-Eluting Coronary Stent Thrombosis.Am J Cardiol. 2009; 103: 806-811https://doi.org/10.1016/j.amjcard.2008.11.048
- Effect of CYP2C19 polymorphisms on the platelet response to clopidogrel and influence on the effect of high versus standard dose clopidogrel in carotid artery stenting.Eur J Vasc Endovasc Surg. 2016; 51: 175-186https://doi.org/10.1016/j.ejvs.2015.09.020
- CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: A case-control study.Eur Heart J. 2010; 31: 3046-3053https://doi.org/10.1093/eurheartj/ehq321
- Reduced clopidogrel metabolism in a multiethnic population: Prevalence and rates of recurrent cerebrovascular events.J Stroke Cerebrovasc Dis. 2014; 23: 694-698https://doi.org/10.1016/j.jstrokecerebrovasdis.2013.06.008
- Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: Results of the ACCEL-DOUBLE (Accelerated platelet inhibition by a double dose of clopidogrel ac.JACC Cardiovasc Interv. 2010; 3: 731-741https://doi.org/10.1016/j.jcin.2010.05.007
- CYP2C19 polymorphisms and antiplatelet effects of clopidogrel in acute ischemic stroke in China.Stroke. 2013; 44: 1717-1719https://doi.org/10.1161/STROKEAHA.113.000823
Komarov A, Shakhmatova O, Donnikov A, Ilyushchenko T, Dzhalilova G, Panchenko E. Carrying of P450 2C19*2 polymorphism and use of proton pump inhibitors increase risk of adverse outcomes after elective PCI in Russian patients with CAD [abstract P491] 2011. https://doi.org/10.1177 /1741826711407011.
- Impact of CYP2C19 polymorphisms on antiplatelet efficacy of clopidogrel in patients after myocardial infarction.Folia Medica Copernicana. 2013; 1: 12-17
- Clinical Outcomes and Sustainability of Using CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.Circ Genomic Precis Med. 2018; 11e002069https://doi.org/10.1161/CIRCGEN.117.002069
- Association of PON1, P2Y12 and COX1 with recurrent ischemic events in patients with extracranial or intracranial stenting.PLoS One. 2016; 11: 1-12https://doi.org/10.1371/journal.pone.0148891
- The association between CYP2C19 genotype and of in-stent restenosis among patients with vertebral artery stent treatment.CNS Neurosci Ther. 2014; 20: 125-130https://doi.org/10.1111/cns.12173
- Dual therapy with clopidogrel and aspirin prevents early neurological deterioration in ischemic stroke patients carrying CYP2C19*2 reduced-function alleles.Eur J Clin Pharmacol. 2018; 74: 1131-1140https://doi.org/10.1007/s00228-018-2468-7
- The correlation between recurrent risk and CYP2C19 gene polymorphisms in patients with ischemic stroke treated with clopidogrel for prevention.Medicine (Baltimore). 2020; 99: e19143https://doi.org/10.1097/MD.0000000000019143
- Relationship between cytochrome P450 2C19*2 polymorphism and stent thrombosis following percutaneous coronary intervention in Chinese patients receiving clopidogrel.J Int Med Res. 2011; 39: 2012-2019https://doi.org/10.1177/147323001103900548
- Coexisting polymorphisms of P2Y12 and CYP2C19 genes as a risk factor for persistent platelet activation with clopidogrel.Circ J. 2008; 72: 1165-1169https://doi.org/10.1253/circj.72.1165
- Cytochrome P450 2C19 Polymorphism, Suboptimal Reperfusion and All-Cause Mortality in Patients with Acute Myocardial Infarction.Cardiology. 2010; 117: 81-87
- Frequency and clinical outcomes of CYP2C19 genotype-guided escalation and de-escalation of antiplatelet therapy in a real-world clinical setting.Genet Med. 2020; 22: 160-169https://doi.org/10.1038/s41436-019-0611-1
- CYP2C19 metabolizer status and clopidogrel efficacy in the Secondary Prevention of Small Subcortical Strokes (SPS3) study.J Am Heart Assoc. 2015; 4e001652https://doi.org/10.1161/JAHA.114.001652
- Sequence variations in CYP metabolism genes and cardiovascular outcomes following treatment with clopidogrel: insights from the CLARITYTIMI 28 genomic study.J Am Coll Cardiol. 2008; 51: A206
- Cytochrome p-450 polymorphisms and response to clopidogrel.N Engl J Med. 2009; 360: 354-362https://doi.org/10.1056/NEJMoa0809171
- Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease.JAMA - J Am Med Assoc. 2011; 306: 2221-2228https://doi.org/10.1001/jama.2011.1703
- Effect of Cytochrome P450 2C19 Polymorphism on Target Lesion Outcome After Drug-Eluting Stent Implantation in Japanese Patients Receiving Clopidogrel.Circ J. 2012; 76: 2348-2355https://doi.org/10.1253/circj.CJ-12-0476
- Effects of CYP2C19 allelic variants on inhibition of platelet aggregation and major adverse cardiovascular events in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study.J Cardiol. 2016; 68: 26-36https://doi.org/10.1016/j.jjcc.2015.07.019
- Association of cytochrome P450 2C19*2 polymorphism with clopidogrel response variability and cardiovascular events in Koreans treated with drug-eluting stents.Heart. 2012; 98: 139-144https://doi.org/10.1136/hrt.2011.227272
- Determination of cut-off levels for on-clopidogrel platelet aggregation based on functional CYP2C19 gene variants in patients undergoing elective percutaneous coronary intervention.Thromb Res. 2011; 128: e130-e136https://doi.org/10.1016/j.thromres.2011.07.028
- Effects of CYP2C19 genotype on outcomes of clopidogrel treatment.N Engl J Med. 2010; 363: 1704-1714
- The CYP2C19 genotype does not impact the long-term prognosis of patients with coronary artery disease.Atherosclerosis. 2013; 227: 106-111https://doi.org/10.1016/j.atherosclerosis.2012.12.028
- Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: The GIFT (Genotype Information and Functional Testing) study.J Am Coll Cardiol. 2012; 59: 1928-1937https://doi.org/10.1016/j.jacc.2011.11.068
- Influence of CYP2C19 polymorphisms on platelet reactivity and clinical outcomes in ischemic stroke patients treated with clopidogrel.Eur J Pharmacol. 2015; 747: 29-35https://doi.org/10.1016/j.ejphar.2014.11.037
- The association between high on-treatment platelet reactivity and early recurrence of ischemic events after minor stroke or TIA.Neurol Res. 2017; 39: 719-726https://doi.org/10.1080/01616412.2017.1312793
- Association between CYP2C9 polymorphisms and ischemic stroke following endovascular neurointervention.J Stroke Cerebrovasc Dis. 2020; 29104901https://doi.org/10.1016/j.jstrokecerebrovasdis.2020.104901
- VASP phosphorylation and genetic polymorphism for clopidogrel resistance in Chinese patients with non-cardioembolic ischemic stroke.Thromb Res. 2014; 134: 1272-1277https://doi.org/10.1016/j.thromres.2014.10.001
- Impact of cytochrome P450 2C19*2 polymorphism on intra-stent thrombus after drug-eluting stent implantation in Japanese patients receiving clopidogrel.Circ J. 2011; 75: 99-105https://doi.org/10.1253/circj.CJ-10-0525
- Clinical Value of CYP2C19 genetic testing for guiding the antiplatelet therapy in a Chinese population.J Cardiovasc Pharmacol. 2016; 67: 232-236https://doi.org/10.1097/FJC.0000000000000337
- Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.JAMA - J Am Med Assoc. 2009; 302: 849-858https://doi.org/10.1001/jama.2009.1232
- Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention.Eur Heart J. 2009; 30: 916-922https://doi.org/10.1093/eurheartj/ehp041
- Genetic Determinants of Response to Clopidogrel and Cardiovascular Events.N Engl J Med. 2009; 360: 363-375https://doi.org/10.1056/nejmoa0808227
- CYP2C19 genotype and early ischemic lesion recurrence in stroke patients treated with clopidogrel.J Stroke Cerebrovasc Dis. 2015; 24: 440-446https://doi.org/10.1016/j.jstrokecerebrovasdis.2014.09.014
- Association of CYP2C19 polymorphisms with clopidogrel reactivity and clinical outcomes in chronic ischemic stroke.Circ J. 2019; 83: 1385-1393https://doi.org/10.1253/circj.CJ-18-1386
- Impact of cytochrome P450 2C19 polymorphisms on outcome of cardiovascular events in clopidogrel-treated Chinese patients after percutaneous coronary intervention.Zhonghua Xin Xue Guan Bing Za Zhi. 2011; 39: 617-620
- Effect of the CYP2C19*2 and*3 genotypes, ABCB1 C3435T and PON1 Q192R alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention.Eur J Clin Pharmacol. 2013; 69: 1103-1112https://doi.org/10.1007/s00228-012-1446-8
- Protective effect of the CYP2C19*17 polymorphism with increased activation of clopidogrel on cardiovascular events.Am Heart J. 2010; 160: 506-512https://doi.org/10.1016/j.ahj.2010.06.039
- Impact of CYP2C19 polymorphisms on clinical outcomes and antiplatelet potency of clopidogrel in caucasian poststroke survivors.Am J Ther. 2018; 25: E202-E212https://doi.org/10.1097/MJT.0000000000000416
- Investigating Real-World Clopidogrel Pharmacogenetics in Stroke Using a Bioresource Linked to Electronic Medical Records.Clin Pharmacol Ther. 2018; 103: 281-286https://doi.org/10.1002/cpt.780
- Cytochrome P450 2C19 681G>A Polymorphism and High On-Clopidogrel Platelet Reactivity Associated With Adverse 1-Year Clinical Outcome of Elective Percutaneous Coronary Intervention With Drug-Eluting or Bare-Metal Stents.J Am Coll Cardiol. 2008; 51: 1925-1934https://doi.org/10.1016/j.jacc.2007.12.056
- Prospective CYP2C19 genotyping to guide antiplatelet therapy following percutaneous coronary intervention: A pragmatic randomized clinical trial.Circ Genomic Precis Med. 2020; https://doi.org/10.1161/CIRCGEN.119.002640
- Variant recurrent risk among stroke patients with different CYP2C19 phenotypes and treated with clopidogrel.Platelets. 2015; 26: 558-562https://doi.org/10.3109/09537104.2014.953044
- Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: A genetic substudy of the PLATO trial.Lancet. 2010; 376: 1320-1328https://doi.org/10.1016/S0140-6736(10)61274-3
- Association between CYP2C19 loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack.JAMA - J Am Med Assoc. 2016; 316: 70-78https://doi.org/10.1001/jama.2016.8662
- The presence of the CYP p450 C19*2 allele is associated with impaired response to clopidogrel as measured by the Verify Now P2Y12 near-patient testing device in patients undergoing coronary angiography [abstract P2089].Eur Heart J. 2009; 30: 327
- Influence of Genetic Polymorphisms on Clopidogrel Response and Clinical Outcomes in Patients with Acute Ischemic Stroke CYP2C19 Genotype on Clopidogrel Response.CNS Neurosci Ther. 2015; 21: 692-697https://doi.org/10.1111/cns.12426
- Impact of CYP2C19 polymorphism on residual platelet reactivity in patients with coronary heart disease during antiplatelet therapy.J Cardiol. 2011; 57: 194-201https://doi.org/10.1016/j.jjcc.2010.10.007
- Aspirin plus clopidogrel may reduce the risk of early neurologic deterioration in ischemic stroke patients carrying CYP2C19*2 reduced-function alleles.J Neurol. 2018; 265: 2396-2403https://doi.org/10.1007/s00415-018-8998-1
- Concomitant use of proton-pump inhibitors and clopidogrel increases the risk of adverse outcomes in patients with Ischemic stroke carrying reduced-function CYP2C19*2.Clin Appl Thromb. 2018; 24: 55-62https://doi.org/10.1177/1076029616669787
- Association between cytochrome P450 2C19 681GA polymorphisms and risk of cardiovascular events in coronary heart disease with clopidogrel in Chinese [abstract P1548].Eur Heart J. 2011; 32: 1-312https://doi.org/10.1093/eurheartj/ehr322
- Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China.Eur J Clin Pharmacol. 2018; 74: 423-431https://doi.org/10.1007/s00228-017-2393-1
- Association of CYP2C19 Polymorphisms with the Clinical Efficacy of Clopidogrel Therapy in Patients Undergoing Carotid Artery Stenting in.Asia. Sci Rep. 2016; 6: 21-23https://doi.org/10.1038/srep25478
- Abstract WMP39: Clopidogrel Resistance Predicts Early Neurological Worsening In Patients With Acute Large Artery Atherosclerotic Stroke.Stroke. 2018; 49
- Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: A meta-analysis based on 23,035 subjects.Arch Cardiovasc Dis. 2013; 106: 517-527https://doi.org/10.1016/j.acvd.2013.06.055
- Cytochrome P450 2C19 polymorphism is associated with poor clinical outcomes in coronary artery disease patients treated with clopidogrel.Mol Biol Rep. 2011; 38: 1697-1702https://doi.org/10.1007/s11033-010-0282-0
- CYP2C19*2/ABCB1-C3435T polymorphism and risk of cardiovascular events in coronary artery disease patients on clopidogrel: Is clinical testing helpful?.Indian Heart J. 2012; 64: 341-352https://doi.org/10.1016/j.ihj.2012.06.003
- ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA “Boxed Warning”. A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association Endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons.J Am Coll Cardiol. 2010; 56: 321-341https://doi.org/10.1016/j.jacc.2010.05.0
- Routine screening for CYP2C19 polymorphisms for patients being treated with clopidogrel is not recommended.Hawaii J Med Public Health. 2015; 74: 16-20
- Clinical pharmacogenetics implementation consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.Clin Pharmacol Ther. 2013; 94: 317-323https://doi.org/10.1038/clpt.2013.105
- The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Outcomes and Metrics of Pharmacogenetic Implementations Across Diverse Healthcare Systems.Clin Pharmacol Ther. 2017; 102: 502-510https://doi.org/10.1002/cpt.630
- CYP2C19_Review_Clin Pharmacokinet_2002.pdf.Drug Dispos. 2002; 41: 913-958
- Pharmacogenetics of clopidogrel.Circ Cardiovasc Genet. 2016; 9: 185-188https://doi.org/10.1161/CIRCGENETICS.115.001318
- Meta-analysis of cytochrome P450 2C19 polymorphism and risk of adverse clinical outcomes among coronary artery disease patients of different ethnic groups treated with clopidogrel.Am J Cardiol. 2012; 110: 502-508https://doi.org/10.1016/j.amjcard.2012.04.020
- Pharmacogenetic landscape of clopidogrel in north Indians suggest distinct interpopulation differences in allele frequencies.Pharmacogenomics. 2014; 15: 643-653https://doi.org/10.2217/pgs.13.241
- Effect of CYP2C19 *2 and *23 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin.Circ Cardio vasc Interv. 2011; 4: 585-594https://doi.org/10.1161/CIRCINTERVENTIONS.111.962555
- Intraprocedural thrombotic event during coronary intervention depends on CYP2C19 genotype and is a predictor of future clinical event.Int J Cardiol. 2015; 187: 231-233https://doi.org/10.1016/j.ijcard.2015.03.345
- Impact of CYP2C19 polymorphism and proton pump inhibitors on platelet reactivity to clopidogrel and clinical outcomes following stent implantation.Thromb Res. 2014; 133: 599-605https://doi.org/10.1016/j.thromres.2014.01.003
- CYP2C19 poor metabolizer is associated with clinical outcome of clopidogrel therapy in acute myocardial infarction but not stable angina.Circ Cardiovasc Genet. 2013; 6: 514-521https://doi.org/10.1161/CIRCGENETICS.113.000109